Format

Send to

Choose Destination
Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):161-167. doi: 10.1002/pds.4351. Epub 2017 Nov 17.

Pediatric drug information available at the time of new drug approvals: A cross-sectional analysis.

Author information

1
Division of Emergency Medicine, Boston Children's Hospital, Boston, MA, USA.
2
Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
3
Department of Emergency Medicine, Harvard Medical School, Boston, MA, USA.
4
Division of Pediatric and Maternal Health, Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
5
Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.

Abstract

PURPOSE:

Greater than 50% of drugs lack pediatric labeling information, resulting in widespread "off-label" use in children. To increase pediatric prescribing information, the Pediatric Research Equity Act (PREA) was passed in 2003, requiring new drug applications to include pediatric assessments. We evaluated the study of new drugs in children since PREA was implemented.

METHODS:

We performed a cross-sectional analysis of new drug applications submitted to the FDA from December 2003 to July 2012, using publicly available documents at Drugs@FDA. We calculated the proportion of new drugs that included a pediatric assessment at the time of approval and at a final review performed in July 2016.

RESULTS:

We identified 92 new drugs requiring pediatric assessments. Only 20 (21.7%) had been fully studied in children at the time of approval, while 9 (9.8%) had been partially assessed, and 63 (68.5%) did not have pediatric data. Among drugs approved without pediatric assessments, 4.2% met FDA deferral deadlines and 34.9% eventually submitted pediatric data. At the time of our final review, allowing for a mean of 8.6 years since drug approval, 57.6% of new drugs had not been fully assessed in children. The mean time between approval in adults and availability of pediatric data for drugs approved without pediatric assessments was 6.5 years.

CONCLUSIONS:

These results represent a comprehensive evaluation of the study of new drugs in children and demonstrate that many drugs continue to be approved without pediatric data. Our findings serve to inform approaches to strengthen adherence to PREA requirements.

KEYWORDS:

Pediatric Research Equity Act; pediatric drug development; pharmacoepidemiology; regulatory science

PMID:
29148107
DOI:
10.1002/pds.4351

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center